Last reviewed · How we verify
Cyclosporine 0.010%
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. Used for Dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | Cyclosporine 0.010% |
|---|---|
| Sponsor | Allergan |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell activation and IL-2 production. In ocular tissues, this immunosuppressive effect reduces inflammation and increases tear production, making it effective for dry eye disease where immune-mediated tear gland dysfunction is a primary pathology.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Ocular irritation or burning
- Conjunctival erythema
- Blurred vision
- Foreign body sensation
Key clinical trials
- Study of Cyclosporine in Post-LASIK Patients (PHASE2)
- Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine 0.010% CI brief — competitive landscape report
- Cyclosporine 0.010% updates RSS · CI watch RSS
- Allergan portfolio CI